DRUG · Mapped RxNorm record
epirubicin
Normalized identity: epirubicinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
cyclophosphamide
Normalized identity: cyclophosphamideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
trastuzumab
Normalized identity: trastuzumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNeoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Neoplasmverified · MONDO: breast neoplasm
Interventions
epirubicinDRUG · verified · RxNorm: epirubicin
cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
docetaxelDRUG · verified · RxNorm: docetaxel
trastuzumabDRUG · verified · RxNorm: trastuzumab
Sponsors & collaborators
Accelerated Community Oncology Research Networklead sponsor
Aventis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00270894 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.